Jun 15, 2024, 05:47
Nicholas Hornstein: Cholangiocarcinoma patients post gemcitabine based treatment by Arndt Vogel et al
Nicholas Hornstein, Oncology Fellow at MD Anderson Cancer Center, shared a post on X:
“Phase 2 Trial
100 Cholangiocarcinoma patients post gemcitabine based treatment
5-FU + nal-IRI vs 5-FU
DFS 2.6 vs 2.3 months; negative trial
2 drugs vs 1 trial design raise question of underlying efficacy of nal-IRI in cholangiocarcinoma!”
Read further.
Source: Nicholas Hornstein/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18